Despite a long line of evidence showing PAR-2 expression and activation in diseased GI tract, such as reflux-associated esophagitis or gastroesophageal reflux disease (GERD), colitis, acute pancreatitis and gastric ulcer[22]–[25], there are no studies to date whether PAR-2 plays a role in Barrett’s esophagus. Here, F2RL1 is linked to esophageal adenocarcinoma.